Literature DB >> 26898438

Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression.

Lei Wang1, Xiu-Li Guo2.   

Abstract

Galectin-3, a multifunctional protein, distributes inside and outside cells and plays an important role in tumor cell adhesion, proliferation, differentiation, angiogenesis, and metastasis in multiple tumors. Changes in galectin-3 expression are commonly seen in cancer and pre-cancerous conditions. Therefore, to understand the molecular regulation of galectin-3 expression could aid the development of new approach for cancer treatment. This review summarizes different expression of galectin-3 in cancer cells and patients' serum, the regulation mechanism and the potential therapeutic targets of galectin-3 in cancer progression.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer; Galectin-3; Inflammatory cytokines; Ras/MAPK pathway; Regulation mechanism; Transcription factors

Mesh：

Substances：

Year:  2016        PMID： 26898438     DOI： 10.1016/j.biopha.2016.01.014

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  31 in total

Review 1.  Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.

Authors:  Ken Shirabe; Yuki Bekki; Dolgormaa Gantumur; Kenichiro Araki; Norihiro Ishii; Atsushi Kuno; Hisashi Narimatsu; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2018-01-09       Impact factor: 7.527

2.  Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases.

Authors:  Fen Ji; Shuqin Zhang; Xia Jiang; Yuyin Xu; Zhiwei Chen; Yaping Fan; Wenjuan Wang
Journal:  J Clin Lab Anal       Date:  2016-10-11       Impact factor: 2.352

Review 3.  Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.

Authors:  Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale
Journal:  Front Cardiovasc Med       Date:  2022-07-06

4.  Prognostic Factors in Acute Myeloid Leukemia with t(8;21)/AML1-ETO: Strategies to Define High-Risk Patients.

Authors:  Jianyong Wang; Na Gao; Xuexia Wang; Wenzheng Yu; Aimin Li
Journal:  Indian J Hematol Blood Transfus       Date:  2021-12-01       Impact factor: 0.915

Review 5.  Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

6.  Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3.

Authors:  Tian Fang; Dan-Dan Liu; He-Ming Ning; Jing-Ya Sun; Xiao-Jing Huang; Yu Dong; Mei-Yu Geng; Shi-Feng Yun; Jun Yan; Rui-Min Huang
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

7.  THE ASSOCIATION BETWEEN LYMPH NODE METASTASIS AND MOLECULAR MARKERS IN DIFFERENTIATED THYROID CANCER.

Authors:  B I Aydoğan; C C Ersöz; S D Sak; S Güllü
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jan-Mar       Impact factor: 0.877

8.  Synthesis of tricyclic carbohydrate-benzene hybrids as selective inhibitors of galectin-1 and galectin-8 N-terminal domains.

Authors:  Chunxia Wu; Can Yong; Qiuju Zhong; Zhouyu Wang; Ulf J Nilsson; Yuanyuan Zhang
Journal:  RSC Adv       Date:  2020-05-22       Impact factor: 3.361

Review 9.  Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments.

Authors:  Ana Carolina Ferreira Cardoso; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Oncol       Date:  2016-05-23       Impact factor: 6.244

10.  Quantitative Analysis of Galectin-3 Expression in Benign and Malignant Thyroid Nodules.

Authors:  Ivan Šamija; Neven Mateša; Sanja Tadinac; Tomislav Jukić
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.